{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T12:13:34Z","timestamp":1788783214769,"version":"build-2803163510"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T00:00:00Z","timestamp":1788739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T00:00:00Z","timestamp":1788739200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmol Ther"],"DOI":"10.1007\/s40123-026-01490-2","type":"journal-article","created":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T11:56:30Z","timestamp":1788782190000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Selecting Vehicle Comparators in Dry Eye Disease Clinical Trials: Implications for Efficacy and Safety Assessment and Regulatory Outcomes"],"prefix":"10.1007","author":[{"given":"Isabella","family":"Tunon-Robinson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cathy","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley K.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Gomez-Freeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,7]]},"reference":[{"key":"1490_CR1","unstructured":"Hom MM, Simmons PA. Understanding emulsion eye drop technology. Rev Optom. 2003;140:03. https:\/\/www.reviewofoptometry.com\/article\/understanding-emulsion-eye-drop-technology. Accessed 12 May 2026."},{"key":"1490_CR2","unstructured":"Lewis A, Sheppard J, Nichols K, et al. Pooled safety and efficacy analysis from two 12-week reproxalap dry eye disease trials. American Academy of Optometry (AAOpt) annual meeting, 8\u201311 October 2025; Boston."},{"issue":"10","key":"1490_CR3","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1007\/s40265-025-02218-5","volume":"85","author":"A Lee","year":"2025","unstructured":"Lee A. Acoltremon: first approval. Drugs. 2025;85(10):1307\u201310.","journal-title":"Drugs"},{"issue":"11","key":"1490_CR4","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1016\/j.addr.2005.07.005","volume":"57","author":"A Ludwig","year":"2005","unstructured":"Ludwig A. The use of mucoadhesive polymers in ocular drug delivery. Adv Drug Deliv Rev. 2005;57(11):1595\u2013639.","journal-title":"Adv Drug Deliv Rev"},{"issue":"5","key":"1490_CR5","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1081\/DDC-120003445","volume":"28","author":"IP Kaur","year":"2002","unstructured":"Kaur IP, Kanwar M. Ocular preparations: the formulation approach. Drug Dev Ind Pharm. 2002;28(5):473\u201393.","journal-title":"Drug Dev Ind Pharm"},{"key":"1490_CR6","doi-asserted-by":"publisher","unstructured":"Weng J, Fink MK, Sharma A. A critical appraisal of the physicochemical properties and biological effects of artificial tear ingredients and formulations. Int J Mol Sci. 2023;24(3):2758. https:\/\/doi.org\/10.3390\/ijms24032758.","DOI":"10.3390\/ijms24032758"},{"issue":"1","key":"1490_CR7","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/S0169-409X(98)00055-6","volume":"36","author":"T Loftssona","year":"1999","unstructured":"Loftssona T, Jarvinen T. Cyclodextrins in ophthalmic drug delivery. Adv Drug Deliv Rev. 1999;36(1):59\u201379.","journal-title":"Adv Drug Deliv Rev."},{"issue":"3","key":"1490_CR8","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1021\/mp400484g","volume":"11","author":"Z Rahman","year":"2014","unstructured":"Rahman Z, Xu X, Katragadda U, Krishnaiah YS, Yu L, Khan MA. Quality by design approach for understanding the critical quality attributes of cyclosporine ophthalmic emulsion. Mol Pharm. 2014;11(3):787\u201399.","journal-title":"Mol Pharm."},{"issue":"6","key":"1490_CR9","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/j.drudis.2016.04.002","volume":"21","author":"P Agarwal","year":"2016","unstructured":"Agarwal P, Rupenthal ID. Modern approaches to the ocular delivery of cyclosporine A. Drug Discov Today. 2016;21(6):977\u201388.","journal-title":"Drug Discov Today"},{"issue":"1","key":"1490_CR10","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/aos.14861","volume":"100","author":"T Loftsson","year":"2022","unstructured":"Loftsson T, Stefansson E. Aqueous eye drops containing drug\/cyclodextrin nanoparticles deliver therapeutic drug concentrations to both anterior and posterior segment. Acta Ophthalmol. 2022;100(1):7\u201325.","journal-title":"Acta Ophthalmol."},{"key":"1490_CR11","doi-asserted-by":"crossref","unstructured":"Stef\u00e1nsson E, Th\u00f3risd\u00f3ttir S, Gu\u0111mundsson \u00d3G, Loftsson T, Fri\u0111riksd\u00f3ttir H, Kristinsson JK. 2-Hydroxypropyl-\u00df-cyclodextrin in eye drops. Evaluation of artificial tear-drops in human patients. In: Szejtli J, Szente L, editors. Proceedings of the Eighth International Symposium on Cyclodextrins. Dordrecht: Springer Dordrecht; 1996. p. 391\u20134.","DOI":"10.1007\/978-94-011-5448-2_87"},{"key":"1490_CR12","unstructured":"ISRCTN Registry (International Standard Randomised Controlled Trial Number. ISRCTN 10063734). A clinical trial to investigate the safety and clinical performance of hydroxypropyl-beta-cyclodextrin 10% w\/v eye drops in the treatment of dry eye disease. 2021. https:\/\/www.isrctn.com\/editorial\/retrieveFile\/64ad9256-cc4b-4491-b913-39f241fe08eb\/36213."},{"key":"1490_CR13","unstructured":"Novartis Pharmaceuticals Corporation. Xiidra (lifitegrast ophthalmic solution) 5%. Prescribing information. 2023. https:\/\/dailymed.nlm.nih.gov\/dailymed\/fda\/fdaDrugXsl.cfm?setid=8589d376-ac10-4ddb-9c53-2e0c8d5675c4. Accessed 12 May 2026."},{"issue":"1","key":"1490_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.optom.2025.100586","volume":"19","author":"M Aljarousha","year":"2026","unstructured":"Aljarousha M, Beshtawi I, Alghamdi WM, et al. Efficacy of 0.38% and 0.18% sodium hyaluronate ocular lubricants for dry eye: a randomized trial in adult Gazan participants. J Optom. 2026;19(1):100586.","journal-title":"J Optom"},{"issue":"4","key":"1490_CR15","first-page":"221","volume":"21","author":"MA Lemp","year":"1995","unstructured":"Lemp MA. Report of the National Eye Institute\/Industry workshop on clinical trials in dry eyes. CLAO J. 1995;21(4):221\u201332.","journal-title":"CLAO J."},{"issue":"2","key":"1490_CR16","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1097\/ICO.0000000000000038","volume":"33","author":"JR Grubbs Jr.","year":"2014","unstructured":"Grubbs JR Jr., Tolleson-Rinehart S, Huynh K, Davis RM. A review of quality of life measures in dry eye questionnaires. Cornea. 2014;33(2):215\u20138.","journal-title":"Cornea"},{"key":"1490_CR17","unstructured":"Shettle L, Blender N, Cheung M, Vantipalli S, Metzinger JL, Goldstein MH. Safety and efficacy of a novel hydrogel-based cyclosporine intracanalicular insert for the treatment of dry eye disease: a phase 1 study. Presented at: ASCRS annual meeting, 23\u201327 July 2021; Las Vegas. https:\/\/annualmeeting.ascrs.org\/-\/media\/files\/2021-papers\/sps-209\/76276-2021-ascrs_shettle-l-et-al_final-2.pdf."},{"key":"1490_CR18","unstructured":"US Department of Health and Human Services Food and Drug Administration. Dry eye: developing drugs for treatment, guidance for industry. 2020. https:\/\/www.fda.gov\/media\/144594\/download. Accessed 12 May 2026."},{"issue":"2","key":"1490_CR19","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.ophtha.2013.09.015","volume":"121","author":"JD Sheppard","year":"2014","unstructured":"Sheppard JD, Torkildsen GL, Lonsdale JD,et al. Lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: results of the OPUS-1 phase 3 study. Ophthalmology. 2014;121(2):475\u201383.","journal-title":"Ophthalmology."},{"issue":"12","key":"1490_CR20","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1016\/j.ophtha.2015.08.001","volume":"122","author":"J Tauber","year":"2015","unstructured":"Tauber J, Karpecki P, Latkany R, et al. Lifitegrast ophthalmic solution 5.0% versus placebo for treatment of dry eye disease: results of the randomized phase III OPUS-2 study. Ophthalmology. 2015;122(12):2423\u201331.","journal-title":"Ophthalmology."},{"issue":"1","key":"1490_CR21","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.ophtha.2016.09.025","volume":"124","author":"EJ Holland","year":"2017","unstructured":"Holland EJ, Luchs J, Karpecki PM, et al. Lifitegrast for the treatment of dry eye disease: results of a phase III, randomized, double-masked, placebo-controlled trial (OPUS-3). Ophthalmology. 2017;124(1):53\u201360.","journal-title":"Ophthalmology."},{"key":"1490_CR22","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.2147\/OPTH.S110557","volume":"10","author":"CP Semba","year":"2016","unstructured":"Semba CP, Gadek TR. Development of lifitegrast: a novel T-cell inhibitor for the treatment of dry eye disease. Clin Ophthalmol. 2016;10:1083\u201394.","journal-title":"Clin Ophthalmol"},{"key":"1490_CR23","unstructured":"Wickstr\u00f6m K. Dry eyes\u2014regulatory perspectives. EU regulatory workshop\u2014ophthalmology, 27\u201328 October 2011.  https:\/\/www.ema.europa.eu\/en\/documents\/presentation\/presentation-day-2-dry-eyes-regulatory-perspectives_en.pdf. Accessed 12 May 2026."},{"issue":"3","key":"1490_CR24","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.jtos.2017.05.009","volume":"15","author":"GD Novack","year":"2017","unstructured":"Novack GD, Asbell P, Barabino S, et al. TFOS DEWS II clinical trial design report. Ocul Surf. 2017;15(3):629\u201349.","journal-title":"Ocul Surf"},{"issue":"4","key":"1490_CR25","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/S0161-6420(99)00176-1","volume":"107","author":"K Sall","year":"2000","unstructured":"Sall K, Stevenson OD, Mundorf TK, Reis BL. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group. Ophthalmology. 2000;107(4):631\u20139.","journal-title":"Ophthalmology."},{"issue":"9","key":"1490_CR26","volume":"9","author":"CS de Paiva","year":"2019","unstructured":"de Paiva CS, Pflugfelder SC, Ng SM, Akpek EK. Topical cyclosporine A therapy for dry eye syndrome. Cochrane Database Syst Rev. 2019;9(9):CD010051.","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"1490_CR27","doi-asserted-by":"publisher","first-page":"210","DOI":"10.5582\/ddt.2025.01048","volume":"19","author":"Y Zhou","year":"2025","unstructured":"Zhou Y, Zhang W, Sun F. Acoltremon: the first TRPM8 agonist approved for the treatment of dry eye disease. Drug Discov Ther. 2025;19(3):210\u20131.","journal-title":"Drug Discov Ther"},{"issue":"9","key":"1490_CR28","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1080\/17425247.2025.2522947","volume":"22","author":"P Agarwal","year":"2025","unstructured":"Agarwal P, Epitropoulos A, Gaddie I, Galor A, Karpecki P, Schmidt E. All eyes on semifluorinated alkanes: a comprehensive review of the influence of semifluorinated alkane eyedrops on tear film stabilization and drug delivery in dry eye disease. Expert Opin Drug Deliv. 2025;22(9):1359\u201374.","journal-title":"Expert Opin Drug Deliv"},{"key":"1490_CR29","doi-asserted-by":"publisher","unstructured":"Labetoulle M, Benitez-Del-Castillo JM, Barabino S, et al. Artificial tears: biological role of their ingredients in the management of dry eye disease. Int J Mol Sci. 2022;23(5):2434. https:\/\/doi.org\/10.3390\/ijms23052434. Accessed 12 May 2026.","DOI":"10.3390\/ijms23052434"},{"issue":"8","key":"1490_CR30","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1097\/OPX.0b013e3181824de3","volume":"85","author":"JR Paugh","year":"2008","unstructured":"Paugh JR, Nguyen AL, Ketelson HA, Christensen MT, Meadows DL. Precorneal residence time of artificial tears measured in dry eye subjects. Optom Vis Sci. 2008;85(8):725\u201331.","journal-title":"Optom Vis Sci"},{"issue":"5","key":"1490_CR31","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1007\/s11096-022-01439-y","volume":"44","author":"J Prinz","year":"2022","unstructured":"Prinz J, Maffulli N, Fuest M, Walter P, Hildebrand F, Migliorini F. Placebo administration for dry eye disease: a level I evidence based systematic review and meta-analysis. Int J Clin Pharm. 2022;44(5):1087\u2013101.","journal-title":"Int J Clin Pharm"},{"issue":"3","key":"1490_CR32","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.jtos.2017.05.006","volume":"15","author":"L Jones","year":"2017","unstructured":"Jones L, Downie LE, Korb D, et al. TFOS DEWS II management and therapy report. Ocul Surf. 2017;15(3):575\u2013628.","journal-title":"Ocul Surf"},{"key":"1490_CR33","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.ajo.2025.05.039","volume":"279","author":"L Jones","year":"2025","unstructured":"Jones L, Craig JP, Markoulli M, Karpecki P, Akpek EK, Basu S, et al. TFOS DEWS III: management and therapy. Am J Ophthalmol. 2025;279:289\u2013386.","journal-title":"Am J Ophthalmol"},{"key":"1490_CR34","unstructured":"US Department of Health and Human Services Food and Drug Administration. Over-the-counter (OTC) monograph M018: ophthalmic drug products for over-the-counter human use. 2022.  https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/omuf\/monographs\/OTC%20Monograph_M018-Ophthalmic%20Drug%20Products%20for%20OTC%20Human%20Use%2004.04.22.pdf. Accessed 12 May 2026."},{"issue":"5","key":"1490_CR35","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1080\/02713683.2020.1836226","volume":"46","author":"KK Nichols","year":"2021","unstructured":"Nichols KK, Evans DG, Karpecki PM. A comprehensive review of the clinical trials conducted for dry eye disease and the impact of the vehicle comparators in these trials. Curr Eye Res. 2021;46(5):609\u201314.","journal-title":"Curr Eye Res"}],"container-title":["Ophthalmology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-026-01490-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40123-026-01490-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-026-01490-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T11:56:35Z","timestamp":1788782195000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40123-026-01490-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,7]]},"references-count":35,"alternative-id":["1490"],"URL":"https:\/\/doi.org\/10.1007\/s40123-026-01490-2","relation":{},"ISSN":["2193-8245","2193-6528"],"issn-type":[{"value":"2193-8245","type":"print"},{"value":"2193-6528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,7]]},"assertion":[{"value":"4 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Suzanne Zheng, Cathy Zhao, and Ashley K. Nguyen are employees of AbbVie and may hold stock\/stock options. Isabella Tunon-Robinson has no competing interests. Laura Gomez-Freeman is the Director of the Dry Eye Clinic at the University of California San Diego, Department of Ophthalmology and is a consultant for AbbVie.","order":1,"name":"Ethics","label":"Conflicts of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The clinical trial was approved by the Alpha Institutional Review Board (approval no. 2012-201-005), San Clemente, CA, USA. The research adhered to the principles outlined in the Helsinki Declaration of 1964 and its later amendments. The manuscript was written following the principles and guidelines set by the Committee on Publication Ethics in its research and publication practices. The research also complied with our institutional ethical standards of research reporting to uphold standards related to transparency, integrity, authorship, disclosure of conflicts of interest, and ethical conduct in publishing. All subjects provided informed consent to participate in the study and provided consent for publication if no identifying information was included in the manuscript.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}